shape:
TORONTO, February 28, 2024 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB), a digital health artificial intelligence company focused on brain health : DGNMF) today announced the start of testing of CERVAI™, the world's first consumer brain health and wellness AI solution, at the University of Miami Brain Health Center. The initial focus will be on the evaluation of the Brain Health Assessment portion of CERVAI™, which scores brain health through clinically validated assessments of brain resilience, vulnerability, and performance functions.
Figure: Screenshot of Selvai™ online portal
The CERVAI™ brain health assessment was developed by researchers led by James E. Galvin, MD, MPH, PhD, of the University of Miami Miller School of Medicine, and is designed to assess a patient's risk of developing diseases such as Alzheimer's disease (“AD”) . Neurology through a series of advanced tests that combine three measures to determine dementia risk: the Resilience Index (“RI”), the Vulnerability Index (“VI”), and the Numeric Symbol Coding Task (“NSCT”). diagnose problems. Combined, the results can help assess the risk of developing AD and other related conditions. Essentially, it aims to “take a snapshot” of a patient's brain health.
In a cross-sectional study, Galvin et al. evaluated 230 participants (71 controls, 71 with mild cognitive impairment, and 88 with Alzheimer's disease and related disorders). Researchers determined VI and RI scores from physical assessments, lifestyle questionnaires, demographics, medical history, and neuropsychological testing, including NSCT. The results showed that a participant with an abnormal test score had a 95.7% chance of having the disorder, and his misclassification rate was 9.7%. The platform outperformed the Montreal Cognitive Assessment with a high level of accuracy (area under the curve = 0.923 ± 0.053)¹.
Fabio Chianelli, Chairman and CEO of DiagnaMed, commented: “We are building momentum for the upcoming commercial launch of CERVAI™, the world’s first consumer brain health and wellness solution that estimates brain age and provides a brain health score. Reputable university brain health centers help bridge the gap in physical and cognitive health while enhancing client engagement and designing personalized interventions to improve overall brain health It serves as a validation of CERVAI™'s potential to provide a unique service to clinics seeking solutions.”
The CERVAI™ Brain Health test pilot program continues to be offered to 25 selected clinics in the United States and Canada. Ideal clinics for the pilot program should focus on health and wellness, sports and physical therapy, mental health, chiropractic care, or clinical research in neurological and cognitive disorders.
For more information about CERVAI™ and to participate in the pilot program, please visit https://www.diagnamed.com/hcpartner.
about CERVAI™ Brain Health Platform
Based on research and development at Drexel University and the University of Miami, CERVAI™ combines brain age.™ Estimation and brain health assessment tools aimed at “raising red flags” for potential brain health problems. CERVAI™ can assess whether the brain ages faster or slower than normal aging in healthy people. Brain age is estimated by collecting brain neural activity data using a low-cost and easy-to-use EEG headset and calculating it using a unique machine learning model. Additionally, CERVAI™ can assess whether a person's brain is healthy or in the early stages of cognitive decline. Brain health is scored through clinically validated assessments of brain resilience, vulnerability, and performance function. Individuals can explore personalized diagnostics and interventions, such as medications and lifestyle changes, that may help reduce the progression or progression of cognitive decline.
About DIAGNAMED
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) announced the launch of CERVAI™, the world's first consumer brain health and wellness AI solution aimed at “raising red flags” in the brain. A digital health artificial intelligence company focused on commercialization. Solve health problems by estimating your brain age and providing a brain health score. Visit DiagnaMed.com.
For more information, please contact us below.
Fabio Chianelli
Chairman and CEO
DIAGNAMED HOLDINGS CO., LTD.
Phone: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its regulatory services provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Notes
Certain statements in this news release are forward-looking statements, including regarding future plans and other matters. Forward-looking statements consist of statements that are not purely historical, such as statements regarding beliefs, plans, expectations and intentions regarding the future. Such information typically includes words such as “will”, “may”, “expect”, “could”, “estimate”, “anticipate”, “intend”, “believe”, This can be identified by the use of forward-looking language such as “intended”. ”, “continuation”, its negative form, or similar variations. Readers are cautioned that the assumptions used in preparing forward-looking information may prove to be incorrect. As a result of many known and unknown risks, uncertainties and other factors, events and circumstances may cause actual results to differ materially from those anticipated. Many of these factors include, but are not limited to, business and economic factors. capital market conditions, our ability to manage operating expenses and our dependence on key personnel. Such statements and information are based on a number of assumptions regarding our current and future business strategies, the environment in which we will operate in the future, our anticipated costs and our ability to achieve our goals. Factors that could cause actual results to differ materially from those in forward-looking statements include the continued availability of capital and financing, litigation, the failure of counterparties to fulfill their contractual obligations, and the loss of key employees and consultants. These include losses, general economic conditions, and market conditions. or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include the Company's management's discussion and analysis dated January 29 and for the year ended September 30, 2023 ( “MD&A'') under the caption “Risk Factors.'' , 2024. This is available in the company profile below. www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or the solicitation of an offer to buy in any state, province, territory or jurisdiction in which such offer, solicitation or sale would previously be unlawful; It does not constitute a solicitation or sale. It does not apply to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
source:
-
Klayman, Michael J. et al. “Brain Health Platform: Combining Resilience, Vulnerability, and Performance to Assess Brain Health and Risk for Alzheimer's Disease and Related Diseases.” Alzheimer's Disease Journal: JAD vol. 90,4 (2022) : 1817-1830. doi:10.3233/JAD-220927
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6bcce004-2b84-4019-89cd-4803b483a928.
